A Safety and Efficacy Study of DRM02 in Subjects With Rosacea

Inclusion Criteria: * Male or female 18 to 70 years of age. * Clinical diagnosis of rosacea with a score of 2 or 3 on the Investigator's Global Evaluation (IGE) of Rosacea scale and at least 15 and not more than 40 papules. * Subjects willing to minimize external factors that might trigger rosacea flare-ups. * Male or non-pregnant, non-lactating females. * Signed informed consent. Exclusion Criteria: * Severe self-reported facial sensitivity. * Severe sun sensitivity. * Ocular-only, phymatous rosacea or steroid rosacea. * Use of topical rosacea treatments in the 4 weeks prior to baseline. * Use of systemic corticosteroids within the 4 weeks prior to baseline. * Use of systemic antibiotics in the 4 weeks prior to baseline. * Use of systemic retinoids for in the 6 months prior to baseline. * Use of topical retinoids in the 3 months prior to baseline. * Use of light- or laser-based rosacea treatments in the past 2 months prior to baseline. * Cosmetic procedures within the 2 months prior to baseline. * Use of topical anti-aging medications in the 2 weeks prior to baseline. * Subjects who have poor skin condition within 5 cm of the treatment area. * Subjects who are current drug or alcohol abusers; have a history of immunodeficiency or are a poor medical risk because of other systemic diseases or active uncontrolled infections. * Subjects with an unstable medical condition or a medical condition not adequately controlled with standard medical therapy. * Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days. * Subjects who have a clinically significant laboratory value at screening.